Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and TAP Block for Elderly Colorectal Surgery Prognosis
NCT04516174Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine and ropivacaine hydrochloride liposomal suspension injection in colorectal cancer (CRC) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Prognosis of aged patients at 72 hours. Status: unknown.
02
Drugs
dexmedetomidineropivacaine hydrochloride liposomal suspension injection
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04516174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516174.